A-PVP

Alpha-pyrrolidinopentiophenone (A-PVP, α-PVP), popularly known as "flakka," is a synthetic cathinone and pyrrolidine stimulant that became notorious in the early-to-mid 2010s for a wave of violent and bizarre incidents in the United States, particularly Florida. It is one of the most extensively documented designer stimulants in terms of adverse psychiatric and social outcomes, and represents a cautionary case study in the potential consequences of designer drug proliferation.

A-PVP is a potent, selective norepinephrine-dopamine reuptake inhibitor (NDRI) comparable in potency to MDPV — the most potent cathinone documented in scientific literature. Unlike amphetamine or methcathinone, A-PVP does not act as a transporter substrate and does not cause active neurotransmitter release; it blocks dopamine and norepinephrine reuptake, producing sustained elevated synaptic concentrations. Reddit community knowledge reflects that users seeking the "most euphoric stim" frequently encounter A-PVP, and that questions about why compounds like A-PVP and MDPV cause psychosis are common — reflecting the real-world pattern of psychiatric sequelae.

The defining harm of A-PVP is its extreme compulsive redosing potential and the associated stimulant psychosis. Community experience describes an experience that begins with powerful euphoria and focus but rapidly — within a single session for some users — deteriorates into compulsive use cycles characterized by paranoia, hallucinations, and escalating dysfunction. The "gift from God" framing that appears in community discussion captures the seductive initial quality that makes the subsequent compulsive spiral so dangerous. One community account of stimulant psychosis after a 12-hour compulsive redosing binge illustrates the canonical harm pattern: the initial euphoric rush gives way to a nightmare of paranoia and dysphoria that continues to be chased through redosing.

A-PVP is one of the highest-risk substances in the novel stimulant class. Its combination of extreme potency, short duration of peak effects, powerful compulsive potential, and severe psychiatric risk profile places it alongside MDPV at the apex of the cathinone harm spectrum.